Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug314 | Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test).
Description: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test)
Measure: To determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection Time: At inclusionDescription: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard
Measure: To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection Time: Third week after inclusionDescription: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard
Measure: To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection Time: Third week after inclusionDescription: Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard
Measure: To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection Time: Third week after inclusionDescription: Using ddPCR and RT-qPCR assays
Measure: To determine the agreements between nasopharyngeal samples and oropharyngeal samples Time: At inclusionDescription: Using ddPCR and RT-qPCR assays
Measure: To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays Time: At inclusionDescription: Rate calculated from the date of the first diagnostic procedure to the date of death of any cause
Measure: To assess the 28-day mortality rate Time: Up to the follow-up end (28 days after inclusion)Description: Demographics, type of tumor, type of anticancer, treatment, comorbidities, biological parameters
Measure: To determine potential predictive factors of death among patients' characteristics Time: Up to the follow-up end (28 days after inclusion)Description: After adjusting on main clinical characteristics and treatment type
Measure: To evaluate the over risk of death of patients COVID+ versus COVID- Time: Up to the follow-up end (28 days after inclusion)Description: Comparison of our "in-house" test to the commercial serology test from EUROIMMUN used for the study
Measure: To evaluate the sensibility, specificity and diagnostic accuracy of "in-house" serologic test for the SARS-CoV-2 detection Time: At inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports